## James B Galloway

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2984090/publications.pdf

Version: 2024-02-01

126708 88477 5,740 174 33 70 citations h-index g-index papers 183 183 183 8547 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. New England Journal of Medicine, 2021, 385, 1172-1183.	13.9	734
2	Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Annals of the Rheumatic Diseases, 2010, 69, 522-528.	0.5	606
3	Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology, 2011, 50, 124-131.	0.9	564
4	A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology, 2019, 58, 1755-1766.	0.9	201
5	A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study. Journal of Infection, 2020, 81, 282-288.	1.7	179
6	Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2011, 70, 1810-1814.	0.5	173
7	Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2013, 72, 229-234.	0.5	146
8	Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology, 2013, 52, 91-98.	0.9	116
9	Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212825.	0.5	115
10	Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. ERJ Open Research, 2021, 7, 00655-2020.	1.1	109
11	The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2012, 71, 869-874.	0.5	107
12	BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology, 2017, 56, 865-868.	0.9	106
13	Poor outcome and prolonged persistence of SARSâ€CoVâ€2 RNA in COVIDâ€19 patients with haematological malignancies; King's College Hospital experience. British Journal of Haematology, 2020, 190, e279-e282.	1.2	89
14	Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2017, 76, 497-503.	0.5	88
15	Venous Thromboembolism Risk With JAK Inhibitors: A Metaâ€Analysis. Arthritis and Rheumatology, 2021, 73, 779-788.	2.9	86
16	The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register. Rheumatology, 2018, 57, 835-843.	0.9	83
17	Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2018, 57, 997-1001.	0.9	82
18	A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. Journal of Rheumatology, 2018, 45, 733-744.	1.0	82

#	Article	IF	Citations
19	The evidence base for psychological interventions for rheumatoid arthritis: A systematic review of reviews. International Journal of Nursing Studies, 2018, 82, 20-29.	2.5	65
20	Diagnostic yield of FDG-PET/CT in fever ofÂunknown origin: a systematic review, meta-analysis, and Delphi exercise. Clinical Radiology, 2017, 72, 764-771.	0.5	63
21	Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with antiâ€'TNF therapy: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2011, 70, 1831-1834.	0.5	62
22	The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors. Pharmacological Research, 2019, 147, 104392.	3.1	62
23	The safety of JAK-1 inhibitors. Rheumatology, 2021, 60, ii24-ii30.	0.9	59
24	A review of the musculoskeletal manifestations of sarcoidosis. Rheumatology, 2018, 57, 777-783.	0.9	56
25	Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study. Rheumatology, 2018, 57, 1381-1389.	0.9	52
26	The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye, 2018, 32, 1168-1173.	1.1	52
27	A case-control and cohort study to determine the relationship between ethnic background and severe COVID-19. EClinicalMedicine, 2020, 28, 100574.	3.2	48
28	Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease. JAMA Neurology, 2020, 77, 1514.	4.5	45
29	The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2011, 50, 1341-1342.	0.9	43
30	A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskeletal Disorders, 2016, 17, 322.	0.8	43
31	Predictors of objective cough frequency in pulmonary sarcoidosis. European Respiratory Journal, 2016, 47, 1461-1471.	3.1	43
32	Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes. Journal of Rheumatology, 2018, 45, 1515-1521.	1.0	40
33	A population study of the reported incidence of native joint septic arthritis in the United Kingdom between 1998 and 2013. Rheumatology, 2016, 55, 2176-2180.	0.9	39
34	The Impact of Targeted Rheumatoid Arthritis Pharmacologic Treatment on Mental Health. Arthritis and Rheumatology, 2018, 70, 1377-1391.	2.9	39
35	IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression. Journal of Infection, 2021, 82, 178-185.	1.7	37
36	British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology, 2022, 61, 1760-1768.	0.9	37

#	Article	IF	CITATIONS
37	Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. Expert Opinion on Biological Therapy, 2020, 20, 517-524.	1.4	35
38	Skeletal muscles and Covid-19: a systematic review of rhabdomyolysis and myositis in SARS-CoV-2 infection. Clinical and Experimental Rheumatology, 2022, 40, 329-338.	0.4	33
39	COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort. BMC Nephrology, 2021, 22, 359.	0.8	31
40	Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix: Table 1. Annals of the Rheumatic Diseases, 2013, 72, 143-144.	0.5	30
41	Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys. Health and Quality of Life Outcomes, 2018, 16, 211.	1.0	30
42	Motivational interviewing: relevance in the treatment of rheumatoid arthritis?. Rheumatology, 2016, 55, 1348-1356.	0.9	29
43	Investigating Pleiotropy Between Depression and Autoimmune Diseases Using the UK Biobank. Biological Psychiatry Global Open Science, 2021, 1, 48-58.	1.0	29
44	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut, 2020, 69, gutjnl-2020-321927.	6.1	28
45	Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritisâ€"a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology, 2017, 56, 2004-2014.	0.9	27
46	Patient involvement in rheumatology outpatient service design and delivery: a case study. Health Expectations, 2017, 20, 508-518.	1.1	25
47	Polypharmacy and Unplanned Hospitalizations in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2017, 44, 1786-1793.	1.0	25
48	Overview of IgG4-related aortitis and periaortitis. A decade since their first description. Autoimmunity Reviews, 2020, 19, 102694.	2.5	25
49	Epidemiology of Scleritis in the United Kingdom From 1997 to 2018: Populationâ€Based Analysis of 11 Million Patients and Association Between Scleritis and Infectious and Immuneâ€Mediated Inflammatory Disease. Arthritis and Rheumatology, 2021, 73, 1267-1276.	2.9	25
50	Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2019, 58, 1767-1776.	0.9	24
51	Placebo Response in Rheumatoid Arthritis Clinical Trials. Journal of Rheumatology, 2020, 47, 28-34.	1.0	24
52	Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data. Rheumatology, 2016, 55, 1843-1848.	0.9	23
53	Inpatient COVID-19 mortality has reduced over time: Results from an observational cohort. PLoS ONE, 2022, 17, e0261142.	1.1	23
54	Investigation of Rheumatoid Arthritis Genetic Susceptibility Markers in the Early Rheumatoid Arthritis Study Further Replicates the <i>TRAF1</i> Association with Radiological Damage. Journal of Rheumatology, 2013, 40, 144-156.	1.0	22

#	Article	IF	CITATIONS
55	The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Annals of the Rheumatic Diseases, 2014, 73, 252-255.	0.5	21
56	The relationship between citations, downloads and alternative metrics in rheumatology publications: a bibliometric study. Rheumatology, 2020, 59, 277-280.	0.9	21
57	Rising Incidence of Acute Hospital Admissions due to Gout. Journal of Rheumatology, 2020, 47, 619-623.	1.0	21
58	The infection risks of JAK inhibition. Expert Review of Clinical Immunology, 2022, 18, 253-261.	1.3	21
59	Smoking and common mental disorders in patients with chronic conditions: An analysis of data collected via a web-based screening system. General Hospital Psychiatry, 2017, 45, 12-18.	1.2	20
60	Changing clinical patterns in rheumatoid arthritis management over two decades: sequential observational studies. BMC Musculoskeletal Disorders, 2016, 17, 44.	0.8	19
61	Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 1800-1809.	2.9	18
62	Determining responsiveness and meaningful changes for the Musculoskeletal Health Questionnaire (MSK-HQ) for use across musculoskeletal care pathways. BMJ Open, 2019, 9, e025357.	0.8	17
63	A cross-sectional study of sleep and depression in a rheumatoid arthritis population. Clinical Rheumatology, 2021, 40, 1299-1305.	1.0	17
64	Achievement of NICE quality standards for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis. Rheumatology, 2017, 56, 223-230.	0.9	16
65	Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	16
66	The RA-MAP Consortium: a working model for academia–industry collaboration. Nature Reviews Rheumatology, 2018, 14, 53-60.	3.5	15
67	Monitoring for retinal toxicity in patients taking hydroxychloroquine and chloroquine. Rheumatology, 2019, 58, 3-4.	0.9	15
68	Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial. Trials, 2017, 18, 591.	0.7	14
69	Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial. RMD Open, 2018, 4, e000676.	1.8	14
70	muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. Trials, 2020, 21, 690.	0.7	14
71	Defining and measuring imaging appropriateness in low back pain studies: a scoping review. European Spine Journal, 2020, 29, 519-529.	1.0	14
72	Validation of the Musculoskeletal Health Questionnaire in inflammatory arthritis: a psychometric evaluation. Rheumatology, 2019, 58, 45-51.	0.9	13

#	Article	IF	CITATIONS
73	Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. Rheumatology, 2022, 61, 3930-3938.	0.9	13
74	A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis. BMC Rheumatology, 2020, 4, 70.	0.6	12
75	Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy. Rheumatology, 2018, 57, 596-605.	0.9	12
76	Extreme elevation of ferritin and creatine kinase in primary infection with HIV-1. International Journal of STD and AIDS, 2015, 26, 68-71.	0.5	11
77	Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections. Current Fungal Infection Reports, 2019, 13, 229-243.	0.9	11
78	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. BMJ Open, 2020, 10, e044566.	0.8	11
79	Data quality predicts care quality: findings from a national clinical audit. Arthritis Research and Therapy, 2020, 22, 87.	1.6	11
80	Vaccine hesitancy and access to psoriasis care during the <scp>COVID</scp> â€19 pandemic: findings from a global patientâ€reported crossâ€sectional survey. British Journal of Dermatology, 2022, 187, 254-256.	1.4	11
81	The first national clinical audit for rheumatoid arthritis. British Journal of Nursing, 2016, 25, 613-617.	0.3	10
82	Rheumatoid arthritis – an update for general dental practitioners. British Dental Journal, 2016, 221, 667-673.	0.3	10
83	Patient- and clinician-reported outcomes for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis. Rheumatology, 2017, 56, 231-238.	0.9	10
84	The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study. Rheumatology Advances in Practice, 2020, 4, rkaa041.	0.3	10
85	The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial. Seminars in Arthritis and Rheumatism, 2020, 50, 1182-1190.	1.6	10
86	The impact of COVID-19 on clinical care, self-management and mental health of patients with inflammatory arthritis. Rheumatology Advances in Practice, 2022, 6, rkab095.	0.3	10
87	Patients' and carers' views and expectations about intensive management for moderate rheumatoid arthritis: a qualitative study. Psychology, Health and Medicine, 2016, 21, 918-925.	1.3	9
88	Is there a role of synovial biopsy in drug development?. BMC Musculoskeletal Disorders, 2016, 17, 172.	0.8	9
89	Cardiovascular risk with NSAIDs in rheumatoid arthritis: an analysis using routinely collected data. Rheumatology, 2016, 55, 763-764.	0.9	9
90	Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102035.	1.1	9

#	Article	IF	Citations
91	The ying and yang of fever in rheumatic disease. Clinical Medicine, 2015, 15, 288-291.	0.8	8
92	Variation and implications of treatment decisions in early rheumatoid arthritis: results from a nationwide cohort study. Rheumatology, 2020, 59, 2035-2042.	0.9	8
93	Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?. Arthritis Research and Therapy, 2016, 18, 142.	1.6	7
94	Twitter, #alternativefacts, careless whispers and Rheumatology. Rheumatology, 2018, 57, 773-774.	0.9	7
95	Mobile apps, wearables and the future of technology in rheumatic disease care. Rheumatology, 2019, 58, 1126-1127.	0.9	7
96	Remote Measurement in Rheumatoid Arthritis: Qualitative Analysis of Patient Perspectives. JMIR Formative Research, 2021, 5, e22473.	0.7	6
97	Pulmonary Sarcoidosis in a patient with Multiple Sclerosis on daclizumab monotherapy. Multiple Sclerosis and Related Disorders, 2018, 20, 25-27.	0.9	5
98	COVID-19: opacification score is higher in the right lung and right lung involvement is a better predictor of ICU admission. European Respiratory Journal, 2020, 56, 2002340.	3.1	5
99	A Knowledge Distillation Ensemble Framework for Predicting Short- and Long-Term Hospitalization Outcomes From Electronic Health Records Data. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 423-435.	3.9	5
100	Systematic Review and Metaanalysis of the Reproducibility of Patient Self-reported Joint Counts in Rheumatoid Arthritis. Journal of Rheumatology, 2021, 48, jrheum.201439.	1.0	5
101	The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know. Journal of Rheumatology, 2021, 48, 1201-1204.	1.0	5
102	Improving outcomes for patients hospitalized with gout: a systematic review. Rheumatology, 2021, 61, 90-102.	0.9	5
103	The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey. Clinical and Experimental Rheumatology, 2017, 35, 477-483.	0.4	5
104	Mitigating infection risk with immunotherapy for rheumatoid arthritis. International Journal of Clinical Rheumatology, 2015, 10, 177-193.	0.3	4
105	Cochrane corner: why we still don't know whether anti-TNF biologic therapies impact uveitic macular oedema. Eye, 2019, 33, 1830-1832.	1.1	4
106	Exploring the macro-level, meso-level and micro-level barriers and facilitators to the provision of good quality early inflammatory arthritis (EIA) care in England and Wales. RMD Open, 2021, 7, e001616.	1.8	4
107	Worse outcomes linked to ethnicity for early inflammatory arthritis in England and Wales: a national cohort study. Rheumatology, 2022, 62, 169-180.	0.9	4
108	A Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients. Journal of Biopharmaceutical Statistics, 2013, 23, 461-476.	0.4	3

#	Article	IF	Citations
109	How to manage patients' expectations in rheumatoid arthritis treatment. International Journal of Clinical Rheumatology, 2015, 10, 301-303.	0.3	3
110	Biosimilars in rheumatology: out of the laboratory and into practice. Expert Review of Clinical Immunology, 2016, 12, 697-699.	1.3	3
111	Differentiating Disease Flare From Infection: A Common Problem in Rheumatology. Do 18F-FDG PET/CT Scans and Novel Biomarkers Hold The Answer?. Current Rheumatology Reports, 2018, 20, 70.	2.1	3
112	The use of real-world data to address questions of patient safety. Rheumatology, 2020, 59, 26-30.	0.9	3
113	NEIAA: driving EIA service quality in a shifting clinical landscape. Rheumatology, 2020, 59, 3127-3128.	0.9	3
114	Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. Clinical and Experimental Rheumatology, 0, , .	0.4	3
115	Inflammatory Arthritis in Clinical Practice. , 2015, , .		2
116	Response to: †Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al. Annals of the Rheumatic Diseases, 2017, 76, e4-e4.	0.5	2
117	Comment on: Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy. Rheumatology, 2018, 57, 768-768.	0.9	2
118	Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography. Joint Bone Spine, 2020, 87, 507-508.	0.8	2
119	COVID-19 and mortality in rare rheumatic diseases, a warning bell?. Rheumatology, 2021, 60, 1580-1581.	0.9	2
120	P049 Skeletal muscle involvement in COVID-19 infection: a case report and systematic review. Rheumatology, 2021, 60, .	0.9	2
121	Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. Clinical and Experimental Rheumatology, 2020, 38, 245-256.	0.4	2
122	Hospitalizations for Acute Gout: Process Mapping the Inpatient Journey and Identifying Predictors of Admission. Journal of Rheumatology, 2022, 49, 725-730.	1.0	2
123	Delivering Future Clinical Trials in Rheumatology. Journal of Rheumatology, 2015, 42, 18-20.	1.0	1
124	230â€ $f$ Liver function abnormalities on conventional DMARDs: results from a contemporary cohort. Rheumatology, 2018, 57, .	0.9	1
125	The price of good health care. Rheumatology, 2019, 58, 931-932.	0.9	1
126	E023â€fThe use of CXCl13 as a biomarker in rheumatoid arthritis: a systematic review. Rheumatology, 2019, 58, .	0.9	1

#	Article	IF	Citations
127	Centre effects and case-mix in early rheumatoid arthritis observational cohorts: a narrative review. Rheumatology, 2019, 58, 1991-1999.	0.9	1
128	214â€flf I tweet more about my paper, will I improve my citation index?. Rheumatology, 2019, 58, .	0.9	1
129	O26â€f Non-serious infections in patients with RA: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2020, 59, .	0.9	1
130	EP13 $\hat{a} \in f$ A case of candida albicans septic sacroiliitis complicating severe COVID-19 infection. Rheumatology Advances in Practice, 2020, 4, .	0.3	1
131	Rheumatology care of migrants from sub-Saharan Africa: a literature review and qualitative pilot study of patients' perspectives. Clinical Rheumatology, 2020, 40, 3429-3438.	1.0	1
132	Baseline retinal testing is no longer recommended for hydroxychloroquine users in the United Kingdom. Rheumatology, 2021, 60, 2037-2039.	0.9	1
133	P090 Validation of hospital episode statistics data to enable national registration of idiopathic inflammatory myopathies. Rheumatology, 2021, 60, .	0.9	1
134	Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme. Programme Grants for Applied Research, 2021, 9, 1-186.	0.4	1
135	Diarrhoea and preadmission antibiotic exposure in COVID-19: a retrospective cohort study of 1153 hospitalised patients. BMJ Open Gastroenterology, 2021, 8, e000593.	1.1	1
136	185â€A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study. Emergency Medicine Journal, 2020, 37, 843.3-844.	0.4	1
137	EP21â€∫Tumour necrosis factor inhibitor for the treatment of refractory extra-pulmonary disease including sarcoid arthritis and myositis. Rheumatology Advances in Practice, 2020, 4, .	0.3	1
138	When should we start screening for hydroxychloroquine retinopathy?. Rheumatology, 2022, 61, 3097-3098.	0.9	1
139	JAK inhibitors: special issue foreword. Expert Review of Clinical Immunology, 2022, 18, 179-180.	1.3	1
140	108.â€fReview of the Inclusion Criteria of Clinical Trials in PSA with a Comparison with Routine Care Cohort. Rheumatology, 2015, , .	0.9	0
141	O36â€fThe Increasing Incidence of Septic Arthritis in England Between 1998 and 2013. Rheumatology, 0, , .	0.9	0
142	$114\hat{a} \in f$ Experiences of Treatment Decision-Making and Self-Management for Working-Age People with Symptomatic Osteoarthritis of the Knee. Rheumatology, 2016, , .	0.9	0
143	091â€fRationalising the Treatment Target in Rheumatoid Arthritis: Defining the Optimal 28-Joint Das Cut-Off to Determine Good Function and Normal Health-Related Quality of Life. Rheumatology, 2016, , .	0.9	0
144	028â€fThe Incidence and Predictors of Flare in a Cohort of Rheumatoid Arthritis Patients. Rheumatology, 2016, , .	0.9	0

#	Article	IF	CITATIONS
145	O04â€fReturn of the king: rising incidence of gout in England 2006-2017 (Young investigator award) Tj ETQq1 1	0,784314	ł rgBT /Over
146	70.â€∫Sporotrichosis of the tongue. Rheumatology Advances in Practice, 2018, 2, .	0.3	0
147	i026 National Arthritis Audit IT portal. Rheumatology, 2018, 57, .	0.9	O
148	O06â€fHydroxychloroquine use, risk of retinal toxicity, and potential impact of screening in a large tertiary centre. Rheumatology, 2018, 57, .	0.9	0
149	229â€∱The impact of the EIA clinic on early RA care. Rheumatology, 2018, 57, .	0.9	O
150	Better is possible. Rheumatology, 2019, 58, 741-742.	0.9	0
151	17.â€∱Tick-borne relapsing fever: a fever syndrome mimic. Rheumatology Advances in Practice, 2019, 3, .	0.3	О
152	075â€∫Summary of findings from the Burden of Rheumatoid Arthritis across Europe Socioeconomic Survey (BRASS). Rheumatology, 2019, 58, .	0.9	0
153	209â€fQuantifying care variation: the keystone of national quality improvement. Rheumatology, 2019, 58, .	0.9	О
154	Reply. Arthritis and Rheumatology, 2019, 71, 1025-1026.	2.9	0
155	I004â€∫Initial findings from the National Early Inflammatory Arthritis Audit. Rheumatology, 2019, 58, .	0.9	О
156	145 The British Society for Rheumatology's Choosing Wisely UK recommendations. Rheumatology, 2019, 58, .	0.9	0
157	AB0372â€EXPLORING REFRACTORY DISEASE & DISEASE & STENT SYMPTOMS IN RA/POLYJIA DESPITE BDMARDS PATIENT & PROFESSIONAL EXPERIENCES., 2019,,.	5:	O
158	AB0553â€STUDY OF ANXIETY AND DEPRESSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). 2019, , .	,	0
159	AB0247â€INSIGHTS INTO ADHERENCE AND PATIENT-INITIATED MONOTHERAPY FOR RHEUMATOID ARTHRITIS A GLOBAL SURVEY OF PATIENTS, CAREGIVERS AND PHYSICIANS., 2019,,.	VIΑ	O
160	EP44â€∱Taking eosinophilia more seriously. Rheumatology, 2020, 59, .	0.9	0
161	P192â€fCrystallising care: improving hospital gout management. Rheumatology, 2020, 59, .	0.9	O
162	P228â€∫Risk of sinusitis in patients with rheumatoid arthritis: association with different treatment strategies. Rheumatology, 2020, 59, .	0.9	0

#	Article	IF	CITATIONS
163	O19â€∫Secukinumab-related gastrointestinal safety in PsA and AS. Rheumatology, 2020, 59, .	0.9	О
164	P65â€∫Exploring ethnic disparities in early arthritis care. Rheumatology, 2020, 59, .	0.9	0
165	P110 Developing a digital interface for outpatient rheumatology. Rheumatology, 2020, 59, .	0.9	O
166	Recurrent acute pericarditis diagnosed by extra-cellular volume maps. European Heart Journal, 2021, , .	1.0	0
167	Anti-Tumour Necrosis Factor-Alpha (TNF-α) Treatment. , 2015, , 119-135.		O
168	The evidence for biologic immunotherapy in Sarcoidosis: A systematic review. Australasian Medical Journal, 2017, 10, .	0.1	0
169	EP23 $\hat{a} \in f$ Symptomatic sarcoid myopathy: a rare extra-pulmonary manifestation of sarcoidosis. Rheumatology Advances in Practice, 2020, 4, .	0.3	O
170	Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
171	P022â€fAudit of vitamin D and calcium level monitoring in sarcoidosis patients taking calcium and/or vitamin D supplements. Rheumatology, 2022, 61, .	0.9	0
172	P099 $\hat{a} \in f$ Invasive listeriosis in patients with immune-mediated inflammatory diseases on biologics and targeted therapies - a review of the literature. Rheumatology, 2022, 61, .	0.9	0
173	P223â€∫Predictors of mortality in idiopathic inflammatory myopathy-associated interstitial lung disease - a systematic review and meta-analysis. Rheumatology, 2022, 61, .	0.9	0
174	P074 $\hat{a} \in f$ Evaluation of incidence of COVID-19 infection and uptake of COVID-19 vaccine in sarcoidosis patients at a tertiary centre. Rheumatology, 2022, 61, .	0.9	0